{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02040844: Phase 3 Interventional Completed Cat Allergy
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lusvertikimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:telpegfilgrastim [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04034485: Phase 3 Interventional Completed Homozygous Familial Hypercholesterolemia
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tadocizumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:izeltabart tapatansine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04659109: Phase 2 Interventional Completed SARS-CoV Infection
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00583830: Phase 2 Interventional Completed Non Small Cell Lung Cancer
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03291249: Phase 2 Interventional Withdrawn NASH - Nonalcoholic Steatohepatitis
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01821118: Phase 2 Interventional Completed Cerebral Amyloid Angiopathy
(2013)
Source URL:
Class:
PROTEIN
